• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (from parent cell line).
  

PubMed=16902972; DOI=10.1002/pros.20488
Xu J.-C., Wang R.-X., Xie Z.-H., Odero-Marah V., Pathak S., Multani A.S., Chung L.W.K., Zhau H.-Y.E.
Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis.
Prostate 66:1664-1673(2006)

PubMed=21625216; DOI=10.1038/onc.2011.199; PMCID=PMC3165108
Zhang S.-M., Wang X., Osunkoya A.O., Iqbal S.A., Wang Y., Chen Z., Muller S., Chen Z.-J., Josson S., Coleman I.M., Nelson P.S., Wang Y.-Q.A., Wang R.-X., Shin D.M., Marshall F.F., Kucuk O., Chung L.W.K., Zhau H.-Y.E., Wu D.-Q.
EPLIN downregulation promotes epithelial-mesenchymal transition in prostate cancer cells and correlates with clinical lymph node metastasis.
Oncogene 30:4941-4952(2011)

PubMed=32231998; DOI=10.3389/fonc.2020.00292; PMCID=PMC7082744
Rao S.R., Howarth A., Kratschmer P., Snaith A.E., Yapp C., Ebner D., Hamdy F.C., Edwards C.M.
Transcriptomic and functional screens reveal microRNAs that modulate prostate cancer metastasis.
Front. Oncol. 10:292.1-292.15(2020)